Advanced Biological Laboratories (ABL) S.A. and Bio-Active Co., Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand.

See current channel partners.

ABL will be attending the next MEDICA forum in Dusseldorf from 12 – 15 November 2018:

Our team will provide information on our portfolio:

Laboratories, virologists and microbiologists:

• DeepChek® Assays (Genotyping & Drug Resistance)
• UltraGene® Assays (Viral Load Detection)
• DeepChek®, SeqHepB® (Software systems for Sanger or NGS sequencing data management)
• Application: HIV, HBV, HCV, CMV, HSV, TB…

If you were to attend such an event as well, we would be pleased to have a chance to meet you there and catch-up!
Shall it be the case, please do not hesitate to contact us.

Thank you.
With best regards,

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Illumina iSeq 100 Sequencing System.

Download the technical note for more information.

ABL is pleased to announce the immediate availability of a new DeepChek® Assay intended to be used for Herpes Simplex Virus (HSV) genotyping and for determining the presence of mutations within UL23 (thymidine kinase) and UL30 (DNA polymerase) conferring drug resistance to antiviral drugs – DEEPCHEK®-HSV TK/POL ASSAY

CDL Pharma, an ABL Group’s affiliate, obtained the renewal of conformity certification of its Quality System, in compliance with the standard UNI EN ISO 9001:2015.

We focus to provide our customers high quality products and services which satisfy all requirements from applicable regulations and standards, product type approvals and our customers. Certification under ISO standards is an assurance that all processes and documentation are managed efficiently. The confirmation of ISO 9001 certification demonstrates CDL Pharma and ABL’s commitment to work according the latest quality standards and focus on continuous improvement for you, our customer.

We are delighted to announce you that Advanced Biological Laboratories (ABL – https://www.ablsa.com) has just signed a definitive agreement to acquire CDL Pharma (http://www.cdlpharma.com/), a company headquartered in France – see the full press release.

CDL Pharma

• Provides comprehensive biological sample management solutions in clinical research, designed for pharmaceutical laboratories, CROs, biotechnology companies, and all participants in biomedical research:
  • designs, produces and organizes the distribution of sampling kits from related-specific projects;
  • provides international logistic support, as well as collection, processing and storage of biological samples at short, medium and long-term storage (-196°C, -80°C, -20°C, +4°C and room temperature);
  • proposes data management services related to biological samples.
• Is also specialized in the manufacturing of in-vitro diagnostic kits in the field of immunology, molecular biology and infectious diseases through the quality management standard ISO 9001:2015.

For any information or if you have needs for manufacturing kits intended to be used by laboratories or in the context of clinical studies, please feel free to contact our team: CDL@ablsa.com.

This June, the Consorcio Centro de Investigación Biomédica en Red, M.P. – CIBER, the Advanced Biological Laboratories S.A. – ABL and the Vall d’Hebron Research Institute – VHIR have signed a collaboration agreement to develop an analysis software for the high resolution subtyped results obtained on the research of Hepatitis C virus, and obtained through Next Generation Sequencing methods in the diagnosis field.

This collaboration will create an updated link between the ABL laboratories, who will analyze the results from the deep sequencing by using the software DeepCheck-HCV Next Generation Sequencing. This software will generate a useful report for the clinical practice.

By this means, a new collaboration is created within the frame of software development for the analysis of data generated through Massive Sequencing (NGS), a methodology that has triggered, from the beginning of XXI Century, the movement of personalized medicine. This collaboration will personalize the treatment of the patients infected by Hepatitis C virus by bringing high resolution information.

Example of report of the new software.

Advanced Biological Laboratories S.A. and Seha Connect IT Solutions LLC enter into an exclusive distribution and development collaboration agreement covering 14 countries in the Middle East region. The agreement is effective immediately and covers a large panel of clinical software developed by ABL as well as all the future enhancements on such system. These products will address unmet needs of healthcare stakeholders to analyse and understand their data with an objective to support and improve patient outcomes.

Advanced Biological Laboratories (ABL) S.A. and ROCHEM BIOCARE DE PANAMA, S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Panama.

See current channel partners.

Advanced Biological Laboratories (ABL) S.A. and Laborama Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Lithuania.

See current channel partners.

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for:

• Determining antiviral drug resistance to cidofovir, foscarnet sodium, ganciclovir and maribavir in patients infected with cytomegalovirus (CMV) – DEEPCHEK®-CMV UL54/UL97 ASSAY
• Determining drug resistance to isoniazid and rifampicin in patients infected with TB – DEEPCHEK®-TB RPOB/INHA GENOTYPING ASSAY

ABL and Thermo Fisher Scientific Corporation are pleased to announce the execution of a supply agreement conferring to ABL the ability to combine Thermo Fisher Scientific Corporation’s Genetic Analyzers (3500 Genetic Analyzer, Applied Biosystem SeqStudio Genetic Analyzer…) with its DeepChek and UltraGene Assays for Virology and Microbiology applications.

Contact us for more details.

ABL is pleased to announce the allowance of a new patent covering new Hepatitis B primers and kits hybridizing to DNA or mRNA of the Hepatitis B Virus Polymerase gene.